Project Details
Description
ABSTRACT
The overall goal of this proposal is to provide the training, career development, and mentorship that will result
in the candidate Dr. Carroll’s ability to develop an independent program of research that brings genetic studies
and personalized approaches to commercial smoking cessation treatment to the American Indian and Alaska
Native (AI/AN) population. Dr. Carroll is an Assistant Professor at the University of Minnesota (UMN) School of
Public Health with an appointment at the Masonic Cancer Center. Dr. Carroll completed graduate training in
epidemiology and public health, and undergraduate training in molecular genetics. She completed a two year
postdoctoral fellowship with the UMN Tobacco Research Programs with the support of an NIH T32 gaining
expertise in clinical trials. During the five years of this career development award, Dr. Carroll plans to develop
expertise in genetic contributors to smoking behavior, statistical analysis of genetic data, and qualitative data
skills for understanding barriers to genetic research in AI/AN. These areas of new training are essential for the
candidate to be able to fully serve Tribal communities who wish to embark upon genetic-based research and
approaches to smoking cessation. The candidate has a strong mentorship team that includes world-renowned
academic scientists and liaisons with the AI/AN community, and a relevant career development plan that will
enable her to develop into a successful academic investigator and compete for independent funding through
R01 grant mechanisms. The foundation of the research proposal is an existing collaboration with an AI Tribe
with a commercial smoking prevalence >60%. The goal of Aim I is to examine nicotine metabolism genotype
and phenotype data, which has evidence for optimizing cessation treatment, and relating to biomarkers of
nicotine dose and smoking intensity, and nicotine dependence among AI smokers. The applicant will also
explore social and cultural determinants of smoking behavior and therefore has the potential to provide a
comprehensive picture for why AI smoke at such high rates and have poor quit success. Aim II utilizes focus
groups to assess perceptions of and barriers to participating in genetic studies and genetically-informed
approaches to cessation treatment and ways to overcome barriers among AI smokers and their healthcare
providers. The goal of AIM III is to expand the candidate’s existing collaborations with AI Tribes so that the
candidate can assist more Tribes in developing effective cessation interventions. Ultimately, the completion of
this study will provide evidence of Dr. Carroll’s expertise in collaborating with AI tribes on a focused and highly
feasible genetic study and will allow for her to pursue additional genetic studies and genetically-informed
approaches to smoking cessation treatment in a population with a history of high smoking and low rates of
participating in genetic research. The result of this proposal and investment in the Dr. Carroll’s continued
training have the potential to dramatically reduce commercial cigarette smoking among the AI/AN population.
Status | Active |
---|---|
Effective start/end date | 8/3/20 → 2/28/25 |
Funding
- National Institute on Minority Health and Health Disparities: $123,192.00
- National Institute on Minority Health and Health Disparities: $122,984.00
- National Institute on Minority Health and Health Disparities: $123,228.00
- National Institute on Minority Health and Health Disparities: $136,800.00
- National Institute on Minority Health and Health Disparities: $136,648.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.